Date: March 23rd 2009


 

Expert Workshops at BioTrinity 2009

A record number of partnering requests have been made already at BioTrinity 2009, eclipsing last year with over a week to go. Although the partnering system will be active right up to and throughout the conference, if you leave it too late to get involved- you may find the people you want to meet have a full schedule.

Don't forget to book yourself into some of the ten expert workshops or social networking occasions available at BioTrinity 2009: the Gala Dinner and Pre-Conference Reception will be attended by a large number of R&D companies as well as a number of investors.

There is a diverse choice of excellent workshops that can be booked through the partnering system covering a panopoly of new topics including how Oxford spins out new life sciences companies, acquiring assets from distressed companies, EU rare disease policy, IP strategy and cost control, reimbursement and market access, retention, access to Welcome Trust funding, and opportunities for funding via the Innovative Medicines Initiative.

If you don't get a chance to sign up for workshops via the partnering system, you can still walk in to workshops on the day, but only if there are spaces available after pre-booked delegates have taken their seats. This is also the last call for bag inserts, whether they be promotional brochures or executive toys. See who is attending BioTrinity 2009.

...........................................................................................

Workshop Details:

Purchasing from distressed sellers - tips and traps

Host: Chris Shelley, Partner, Manches LLP

One man's misfortune is another man's fortune. While the current economic downturn may not be good news for some companies, it will also present opportunities for others with cash to spare and an eye for a bargain. However, if you are in a position to purchase assets from a company in distress, you will need to understand that the process is different from a normal transaction. You need to set your approach and expectations accordingly. In this workshop experts from our corporate, employment and intellectual property departments will take you through some of the tips and traps inherent in purchasing financially distressed businesses including managing transfer of risk, ownership of IP, supplier's retention of title claims, retaining leased equipment and use of premises and employment liabilities.

...........................................................................................

Spinning out the Oxford Way

Host: Sue Staunton, Partner, James Cowper and Linda Naylor, Head of Tech Transfer, Isis Innovation

Isis Innovation and James Cowper will discuss the methodologies for spinning out life science based businesses used by the University of Oxford’s technology transfer company.

...........................................................................................

Developments in EU Rare Disease Policy and implications for pipeline products

Host: Wills Hughes-Wilson, Senior Director, Health Policy Europe, Genzyme (US)

In the 10 years since the adoption of the EU’s Orphan Regulation the EU legislative framework has further evolved to take account of new technologies, including cell- and gene-therapies. Recent proposals for the creation of “National Plans” and further cooperation between Member States in sharing information to facilitate market access are also currently under discussion. Genzyme played a leading role in the creation of the EU’s orphan system and has continued to do so. The environment regulating pipeline products has become increasingly complex to navigate, but there is a pathway through.

...........................................................................................

How to streamline IP strategy for dual US and European patent protection and enforcement

Host: Dr Tony Maschio, Partner & Dr Kathleen Williams, Partner & Dr. Candi Soames, Partner, Edwards Angell Palmer & Dodge Innovations LLP

For the vast majority of biopharmaceutical companies, the US is the most important market in terms of potential sales, collaborations and sources of investment. Despite this, for most European companies, IP strategy is designed around a European model and does not take into consideration the particular requirements of US law. In this workshop, European patent attorneys Dr. Candi Soames and Dr. Tony Maschio, together with registered US patent attorney Dr. Kathleen Williams, will explain how to optimise European strategy to obtain the best advantage both in Europe and the US.

...........................................................................................

Patents in the credit crunch: keeping costs down

Hosts: Rebecca Tollervey & Simon Kiddle, Partners, Mewburn Ellis LLP

Working within an IP budget is always a challenge. There is an ongoing need to reduce costs while ensuring that valuable intellectual property is protected and the right expert advice is obtained. We will be discussing how costs can be kept down by careful filing strategies, and identifying points in the life of a patent where savings can be made.

...........................................................................................

Evaluating Innovative Technologies: Reimbursement and Market Access Planning

Host: Adam Barak, VP, Boston Healthcare Associates, Inc

For companies developing innovative technologies, it is essential to prepare to achieve payer endorsement as well as to secure the necessary licences which will enable them to launch their products in a given territory. Payers in all countries have been introducing various means of managing healthcare expenditures, and it therefore behoves a company hoping to secure payment for its technology to know what the payer’s expectations are in order for the technology to achieve reimbursement and enable optimal market access. Similarly, without knowing what the payers’ expectations are, it is very difficult to derive what an optimal in-market price should be or what the international price range should be for the technology and therefore what its value is in terms of sales expectations or its acquisition potential. We will explain the steps and activities needed to determine how a company can evaluate what a technology’s price should be, how it can achieve reimbursement and how the value of the technology can be assessed and appraised.

...........................................................................................

How to retain and motivate key employees when finances are restricted

Host: Rod Cook, Partner, Biotech Personnel

There is clear evidence that redundancy programmes do not always produce the savings expected. Rod will draw on his experience of assisting clients with budget restrictions to discuss ways of either avoiding redundancies or minimising the impact. He will refer to data from the most comprehensive remuneration survey of the UK biotech industry.

...........................................................................................

Accelerated Process Integrated Drug Development

Host: Denis Geffroy, Almac

A new approach to early clinical development using our specialist technologies where appropriate e.g. Biocatalysis, Peptides, Solid State Services. A complete set of solutions aimed at accelerating entry into clinical development; saving on average 1 year from the early clinical development timelines. The RAPIDDTM package includes an integrated set of services (API, Drug Product, Pre-clinical tox and safety studies) speeding up entry into Phase I clinical trials (First in Man).

...........................................................................................

How to Access Wellcome Trust Translational Funding

Host: Richard Seabrook, Head of Business Development and Nick Dunster, Senior Business Analyst, The Wellcome Trust

Technology Transfer at the Wellcome Trust is a committed funder of translational research. Bridging the gap between fundamental medical research and commercial application, Technology Transfer supports both academic researchers and companies by funding applied research and development projects to a stage where they are attractive to a follow-on funder. At this workshop you will hear about R&D projects that have already been funded by the Wellcome Trust and, more importantly, how you can access translational funding to support your research.

...........................................................................................

The IMI opportunities for biotechnology companies

Host: Jackie Hunter, GSK and IMI board member

Jackie will outline the IMI and what opportunities are available for biotech companies to seek funding from the Innovative Medicines Initiative, from the expert perspective of an IMI board member.

...........................................................................................

Thursday 26th March is the last day you can sign up for the excellent Gala Dinner attended by more than 120 delegates, although you have until Monday 30th March to sign up for the Pre-Conference Networking Reception. Take a look at the social programme. Call the OBN office on 01865 594640 to book your choices.

Register today and start partnering with the best at BioTrinity 2009

Register online now! www.biotrinity.com

Register online now at www.biotrinity.com - there is hotel accomodation available

............................................................................................

Thanks to our Sponsors:

............................................................................................

BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network

OBN 

© 2006-2009 OBN

<< Previous: BioTrinity - Keep me informed: Partnering surges at BioTrinity 2009 - just 10 working days left to register

| Archive Index |

Next: BioTrinity - Keep me informed: One week left until BioTrinity 2009 - Record Partnering Activity >>

(archive rss , atom )

this list's archives:


This list is for those who wish to stay informed about developments in the BioTrinity conference programme, to find out when there are new announcements, when the online partnering service and company profiles are online, presentation or sponsorship opportunities, and most importantly when registration opens!

BioTrinity - BioPartnering Meeting and Company Showcase
April 2nd-3rd 2009 - Oxford

Subscribe/Unsubscribe on BioTrinity - Keep me informed

* Required



Powered by Dada Mail 3.0.0 beta 3 - 05/19/08
Copyright © 1999-2008, Simoni Creative.

Go back to Visit the BioTrinity website